These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 30188035)

  • 1. [Trimbow® : twice-daily triple combination for the treatment of COPD].
    Corhay JL; Bonhomme O; Guiot J
    Rev Med Liege; 2018 Sep; 73(9):480-484. PubMed ID: 30188035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide.
    Singh D; Corradi M; Spinola M; Papi A; Usmani OS; Scuri M; Petruzzelli S; Vestbo J
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2917-2928. PubMed ID: 29062229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal.
    Vanfleteren L; Fabbri LM; Papi A; Petruzzelli S; Celli B
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3971-3981. PubMed ID: 30587953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Budesonide/Glycopyrronium/Formoterol: A Review in COPD.
    Heo YA
    Drugs; 2021 Aug; 81(12):1411-1422. PubMed ID: 34342835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Effectiveness of Long-Acting Beta
    Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
    Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide as a combination therapy for chronic obstructive pulmonary disease.
    Kupczyk M; Kuna P
    Expert Rev Respir Med; 2019 Jan; 13(1):5-11. PubMed ID: 30463457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis.
    Bourdin A; Molinari N; Ferguson GT; Singh B; Siddiqui MK; Holmgren U; Ouwens M; Jenkins M; De Nigris E
    Adv Ther; 2021 Jun; 38(6):3089-3112. PubMed ID: 33929661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.
    Papi A; Vestbo J; Fabbri L; Corradi M; Prunier H; Cohuet G; Guasconi A; Montagna I; Vezzoli S; Petruzzelli S; Scuri M; Roche N; Singh D
    Lancet; 2018 Mar; 391(10125):1076-1084. PubMed ID: 29429593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Long-Acting Muscarinic Antagonist/Long-Acting β
    Petite SE
    Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current appraisal of single inhaler triple therapy in COPD.
    Lipworth B; Kuo CR; Jabbal S
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3003-3009. PubMed ID: 30319248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.
    Mapel D; Laliberté F; Roberts MH; Sama SR; Sundaresan D; Pilon D; Lefebvre P; Duh MS; Patel J
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1825-1836. PubMed ID: 28684905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis.
    Calzetta L; Di Marco F; Blasi F; Cazzola M; Centanni S; Micheletto C; Rossi A; Rogliani P
    Pulm Pharmacol Ther; 2019 Dec; 59():101855. PubMed ID: 31639476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Why small particle fixed dose triple therapy? An excursus from COPD pathology to pharmacological treatment evolution.
    Braido F; Corsico AG; Paleari D; Piraino A; Cavalieri L; Scichilone N
    Ther Adv Respir Dis; 2022; 16():17534666211066063. PubMed ID: 35044875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: A retrospective study.
    Bogart M; Stanford RH; Reinsch T; Hull M; Buikema A; Hulbert E
    Respir Med; 2018 Sep; 142():73-80. PubMed ID: 30170806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Role of ICS/LABA on COPD treatment].
    Shibata Y
    Nihon Rinsho; 2016 May; 74(5):827-32. PubMed ID: 27254954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.
    Singh D; Papi A; Corradi M; Pavlišová I; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Vestbo J
    Lancet; 2016 Sep; 388(10048):963-73. PubMed ID: 27598678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials.
    Lai CC; Chen CH; Lin CYH; Wang CY; Wang YH
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1539-1548. PubMed ID: 31371939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Effectiveness and Safety of LABA-LAMA vs LABA-ICS Treatment of COPD in Real-World Clinical Practice.
    Suissa S; Dell'Aniello S; Ernst P
    Chest; 2019 Jun; 155(6):1158-1165. PubMed ID: 30922950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single inhaler triple therapy with extrafine beclomethasone, formoterol, and glycopyrronium for the treatment of chronic obstructive pulmonary disease.
    Singh D
    Expert Opin Pharmacother; 2018 Aug; 19(11):1279-1287. PubMed ID: 29985096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adding a LAMA to ICS/LABA Therapy: A Meta-analysis of Triple Combination Therapy in COPD.
    Calzetta L; Cazzola M; Matera MG; Rogliani P
    Chest; 2019 Apr; 155(4):758-770. PubMed ID: 30660781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.